

MAGNESIUM

PRESENTATION: Ampoules containing magnesium sulphate 50% equivalent to 2mmol/ml: 10ml ampoules.

INDICATION: Correction of hypomagnesaemia. Normal range: 0.7 – 1.0 mmol/l.
Treatment of hypomagnesaemia associated with arrhythmias.
Severe bronchospasm.

DOSE AND ADMINISTRATION: ICU STANDARD INTRAVENOUS INFUSION

For treatment of hypomagnesaemia:

Central administration:

20mmol in 100ml glucose 5% over 4 hours.

Peripheral administration:

20mmol in 250ml glucose 5% over 4 hours.

For treatment of severe acute asthma:

8mmol (2g) in 50mls glucose 5% over 20 minutes, peripherally or centrally.

For treatment of serious arrhythmias:

8mmol (2g) in 50mls glucose 5% over 20 minutes, peripherally or centrally. Dose may be repeated once if necessary.

STABILITY: Physically and chemically stable for 24 hours at room temperature.

ADDITIONAL NOTES: Also stable in sodium chloride 0.9%.

References:

1. Magnesium sulphate 50% Injection. Summary of Product Characteristics. Torbay & South Devon NHS Foundation Trust. Last updated September 2021. [Magnesium Sulfate 50%w/v Solution for Injection or Infusion - Summary of Product Characteristics \(SmPC\) - \(emc\) \(medicines.org.uk\)](#)
Accessed: 14/12/22.
2. BNF App, Version 3.1.7. Updated 23/11/22

Title: Magnesium	
ID: TOPG140612v1	Lead Author: Mairi Cromarty
Category: 1	Document Version; 5
Status Draft/Final: Final	Review Date: December 24
Authoriser; Lothian Critical Care QIT Editorial Board.	Date Authorisation: December 22
Date added to intranet: December 22	
Key Words;	
Comments;	